You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CRISPR

Showing 76 - 99 of 99
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Hodgkin's Lymphoma Trial in China (Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells)

Recruiting
  • Non Hodgkin's Lymphoma
  • Beijing, Beijing, China
  • +12 more
Jun 9, 2022

Neurodegenerative Disease, Hereditary, Mitochondrial Diseases, Optic Atrophy Trial in Buffalo (Mutation analysis)

Recruiting
  • Neurodegenerative Disease, Hereditary
  • +2 more
  • Mutation analysis
  • Buffalo, New York
    UBMD Pediatrics
Mar 3, 2022

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

Classical Lissencephalies and Subcortical Band Heterotopias Trial in Jette (Venipuncture and skin biopsy for RNA extraction)

Not yet recruiting
  • Classical Lissencephalies and Subcortical Band Heterotopias
  • Venipuncture and skin biopsy for RNA extraction
  • Jette, Brussel, Belgium
    UZ Brussel
Jan 7, 2022

Metastatic NSCLC Trial in Chengdu (Cyclophosphamide, PD-1 Knockout T Cells)

Completed
Has Results
  • Metastatic Non-small Cell Lung Cancer
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Dec 19, 2020

Key Diagnosis and Treatment Technology of Genetic and Metabolic

Not yet recruiting
  • Diagnosis ， Treatment， Genetic and Metabolic Liver Disease
  • There is no intervention
  • (no location specified)
Oct 27, 2022

Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, B-cell Lymphoma Trial in Wuhan (Fludarabine + Cyclophosphamide +

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
  • Wuhan, Hubei, China
  • +1 more
Mar 11, 2021

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Recruiting
  • DLBCL
  • +8 more
  • Cardiac MRI
  • Bonn, NRW, Germany
    University Hospital Bonn
Jun 11, 2022

HIV/AIDS Trial in Guangzhou (Arsenic Trioxide)

Recruiting
  • HIV/AIDS
  • Arsenic Trioxide
  • Guangzhou, Guangdong, China
    Guangzhou 8th People's Hospital
Jul 19, 2021

Relapsed/Refractory T-cell Acute Lymphoid Leukaemia Trial in London (Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL))

Recruiting
  • Relapsed/Refractory T-cell Acute Lymphoid Leukaemia
  • Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)
  • London, United Kingdom
    Ilyas Ali
May 25, 2022

Mitochondrial DNA and Nuclear SNPs to Predict Severity of

Recruiting
  • Covid19
    • Athens, Greece
    • +3 more
    Jul 11, 2022

    Lumbar Spine Stenosis Specimens for Identification of

    Not yet recruiting
    • Lumbar Spinal Stenosis
    • +5 more
    • Tc99-PYP or Tc99-HDMP Scan
    • Beverly Hills, California
    • +5 more
    Sep 12, 2023

    CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) Trial

    Not yet recruiting
    • CD5+ Relapsed/Refractory Hematopoietic Malignancies
    • +5 more
    • CT125A cells
    • Cyclophosphamide, fludarabine
    • (no location specified)
    Feb 19, 2021

    Tumors, Pancreatic Trial in United States (GSK3145095, Pembrolizumab)

    Terminated
    Has Results
    • Neoplasms, Pancreatic
    • Indianapolis, Indiana
    • +5 more
    Jul 16, 2020

    Esophageal Cancer Trial in Hangzhou (PD-1 Knockout T Cells)

    Completed
    • Esophageal Cancer
    • PD-1 Knockout T Cells
    • Hangzhou, Zhejiang, China
      Hangzhou Cancer Hospital
    Jun 10, 2019

    Human Papillomavirus-Related Malignant Tumor Trial in Guangzhou (TALEN, CRISPR/Cas9)

    Unknown status
    • Human Papillomavirus-Related Malignant Neoplasm
    • TALEN
    • CRISPR/Cas9
    • Guangzhou, Guangdong, China
      The First Affiliated Hospital of Sun Yat-sen University
    Jun 7, 2017

    HIV-1-infection Trial in Beijing (CCR5 gene modification)

    Unknown status
    • HIV-1-infection
    • CCR5 gene modification
    • Beijing, Beijing, China
      307 Hospital of PLA (Affiliated Hospital of Academy to Military
    May 22, 2017

    PD-1 Knockout Engineered T Cells for Castration Resistant

    Withdrawn
    • Hormone Refractory Prostate Cancer
    • PD-1 Knockout T Cells
    • +2 more
    • Beijing, Beijing, China
      Department of Urology Peking University First Hospital
    Mar 4, 2019

    Invasive Bladder Cancer Stage IV Trial in Beijing (PD-1 Knockout T Cells, Cyclophosphamide, IL-2)

    Withdrawn
    • Invasive Bladder Cancer Stage IV
    • PD-1 Knockout T Cells
    • +2 more
    • Beijing, Beijing, China
      Department of Urology Peking University First Hospital
    Mar 4, 2019

    Metastatic Renal Cell Carcinoma Trial (PD-1 Knockout T Cells, Cyclophosphamide, IL-2)

    Withdrawn
    • Metastatic Renal Cell Carcinoma
    • PD-1 Knockout T Cells
    • +2 more
    • (no location specified)
    Mar 4, 2019

    Acne Vulgaris Trial in Los Angeles (NB01)

    Completed
    Has Results
    • Acne Vulgaris
    • NB01
    • Los Angeles, California
      Dermatology Research Associates
    Jul 10, 2020

    Prostate Cancer Trial in Guangzhou (Therapeutic vaccine, PD-1 Knockout T Cells)

    Unknown status
    • Prostate Cancer
    • Therapeutic vaccine
    • PD-1 Knockout T Cells
    • Guangzhou, Guangdong, China
    • +1 more
    May 3, 2018

    Stage IV Gastric Carcinoma, Stage IV Nasopharyngeal Carcinoma, T-Cell Lymphoma Stage IV Trial in Nanjing (Fludarabine,

    Unknown status
    • Stage IV Gastric Carcinoma
    • +4 more
    • Nanjing, Jiangsu, China
    • +1 more
    Apr 28, 2017

    Advanced Malignant Solid Tumor Trial in Nanjing (Neoantigen Reactive T Cells(NRTs), SHR-1210, Fludarabine)

    Unknown status
    • Advanced Malignant Solid Tumor
    • Neoantigen Reactive T Cells(NRTs)
    • +4 more
    • Nanjing, Jiangsu, China
      The Comprehensive Cancer Centre of Drum Tower Hospital, Medical
    Jun 2, 2017